Leerink Partnrs Predicts Weaker Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Equities research analysts at Leerink Partnrs dropped their Q4 2025 earnings per share estimates for Exact Sciences in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.14 per share for the quarter, down from their prior forecast of $0.22. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.87) per share.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year.

EXAS has been the topic of several other research reports. BTIG Research cut their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday. Wells Fargo & Company assumed coverage on Exact Sciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target on the stock. Piper Sandler boosted their price target on Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, September 12th. The Goldman Sachs Group cut their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Raymond James reissued a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.06.

Exact Sciences Trading Down 23.5 %

NASDAQ:EXAS opened at $54.72 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences has a one year low of $40.62 and a one year high of $79.62. The business’s 50-day simple moving average is $67.14 and its 200 day simple moving average is $56.65. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of -57.00 and a beta of 1.27.

Insider Activity

In other news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.36% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. Private Advisor Group LLC grew its holdings in Exact Sciences by 12.5% in the 1st quarter. Private Advisor Group LLC now owns 26,974 shares of the medical research company’s stock worth $1,863,000 after buying an additional 2,999 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in Exact Sciences by 1.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after buying an additional 200 shares in the last quarter. Motive Wealth Advisors bought a new position in Exact Sciences in the 1st quarter worth approximately $201,000. Oppenheimer & Co. Inc. grew its holdings in Exact Sciences by 1.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,088 shares of the medical research company’s stock worth $1,594,000 after buying an additional 401 shares in the last quarter. Finally, ClariVest Asset Management LLC grew its holdings in Exact Sciences by 32.4% in the 1st quarter. ClariVest Asset Management LLC now owns 25,313 shares of the medical research company’s stock worth $1,748,000 after buying an additional 6,192 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.